Saturday 17 October 2026
Export INM’s income statement to Excel — free account
InMed Pharmaceuticals Inc.
INM Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.32
0.01
−0.75%
Follow INM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 0.73 | 1.43 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (1.76) | (5.39) | |
P/B ratio |
— | — | 0.44 | 0.75 | |
Price to Tangible BV |
— | — | 0.52 | 0.87 | |
EV/Sales |
— | — | (0.46) | (0.08) | |
EV/EBITDA |
— | — | 0.46 | 0.08 | |
EV/Operating CF |
— | — | 0.34 | 0.06 | |
EV/FCF |
— | — | 0.34 | 0.06 | |
Quick Ratio |
1.14 | 2.35 | 4.85 | 6.25 | |
Current Ratio |
1.37 | 3.12 | 5.94 | 6.95 | |
Net Debt/EBITDA |
0.84 | 1.87 | 3.32 | 5.35 | |
Debt/Assets |
0.00% | 0.34% | 1.11% | 1.61% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.02 | |
Asset Turnover |
0.00 | 0.00 | 0.59 | 0.51 | |
Operating CF/Net income |
0.47 | 0.57 | 1.17 | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 76.88% | 51.92% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 197.65% | 136.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.16 | 0.14 | 0.12 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 3.08% | 1.80% | |
Graham Net Nets |
— | — | 1.71 | 1.04 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (279.95%) | (278.42%) | |
Free Cash Flow Yield |
— | — | (185.95%) | (91.45%) | |
Revenue per Share |
0.00 | 0.00 | 0.21 | 0.28 | |
Operating CF per Share |
(0.71) | (0.42) | (0.60) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.71) | (0.42) | (0.60) | (0.41) | |
Cash per Share |
0.54 | 1.28 | 1.77 | 2.37 | |
Shareholders Equity per Share |
0.26 | 1.70 | 2.42 | 2.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.26 | 1.70 | 2.42 | 2.93 | |
Free Cash Flow |
(2.96) | (1.70) | (2.38) | (1.61) | |
Working Capital |
0.72 | 4.68 | 7.31 | 9.25 | |
Net Current Asset Value |
0.72 | 4.65 | 7.18 | 9.03 | |
EV/EBIT |
— | — | 0.32 | 0.06 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.22 | 0.31 | |
Average Payables |
1.54 | 1.21 | 1.22 | 1.07 | |
Average Inventory |
— | — | 1.03 | 1.06 | |
Average Assets |
9.31 | 9.21 | 9.85 | 11.91 | |
Average Common Equity |
7.25 | 6.96 | 7.88 | 9.99 |
Columns are period end dates